I dont know what to think about that article.  It appears to me to just be a filler article with it's brevity and overly simplistc tone.  My gut tells me that Jennifer hasn't done much investigation into Kevetrin but knew enough about it to think a mention of it would make her article look well researched.  I am probably wrong, but that is my initial reaction. 

That said regardless of my gut reaction; the fact that K is getting a more public mention on a site like Forbes is extremely positive.  Jennifer gave just enough information that a curious person, like myself, would likely follow up reading that article with a search on K to see what it was all about.  For example; maybe some big fish investor is wasting time during his/her lunch break, reads this seemingly fluff article, and as a result finds K sooner rather than later.  You never know what potential that could unlock.  The more K trickles into the public eye the faster I think the flood gates will open upon announcements of success in the near future.